The largest community of pharma leaders

Lyndra Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Once-Weekly Rosuvastatin Extended-Release Capsule, LYN-047

WATERTOWN, Mass.–(BUSINESS WIRE)–Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past with the first-ever ultra-long-acting, sustained release oral therapies, today announced the first subject has been dosed in a Phase 1 clinical trial evaluating LYN-047, the Company’s rosuvastatin extended-release capsule, which is being developed for the weekly oral treatment of dyslipidemia. This Phase 1 open-label study is examining the safety, tolera

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles